SlideShare uma empresa Scribd logo
1 de 20
The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
References/Data Source ,[object Object],[object Object],[object Object],[object Object]
Table of Contents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Orphan Drug Act ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Provisions of the Orphan Drug Act: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Governmental Entities Implementing the Orphan Drug Act ,[object Object],[object Object],[object Object]
Has the Orphan Drug Act Met It’s Objectives? ,[object Object],[object Object],[object Object],[object Object]
Findings: ,[object Object],[object Object],[object Object],[object Object]
Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
Findings: ,[object Object],[object Object],[object Object],[object Object]
Conclusion: ,[object Object],[object Object],[object Object]
What Does This Mean To You?: Managed Care Vision Today & Beyond ,[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object]

Mais conteúdo relacionado

Mais procurados

IND INDA ANDA Application
IND INDA ANDA ApplicationIND INDA ANDA Application
IND INDA ANDA ApplicationRoshan Bodhe
 
FDA-Fast Track Designation
FDA-Fast Track DesignationFDA-Fast Track Designation
FDA-Fast Track DesignationVansh Raina
 
Regulatory guidelines of Australia
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australianandiniwarier93
 
Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDr. Vishal Pawar
 
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGSNEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGSManukonda sravani Reddy
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 
PHARMACOVIGILANCE TERMINOLOGIES ASKED IN INTERVIEWS
PHARMACOVIGILANCE TERMINOLOGIES ASKED IN INTERVIEWSPHARMACOVIGILANCE TERMINOLOGIES ASKED IN INTERVIEWS
PHARMACOVIGILANCE TERMINOLOGIES ASKED IN INTERVIEWSPristyn Research Solutions
 
Drug approval in US, EU & India
Drug approval in US, EU & IndiaDrug approval in US, EU & India
Drug approval in US, EU & IndiaSweta Yadav
 
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGSORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGSAshish Bajaj
 
Regulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaRegulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaDr. Pankaj Bablani
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan DrugsANCY JOSE
 
Development safety update report (dsur) pharmacovigilance and safety
Development safety update report (dsur)   pharmacovigilance and safetyDevelopment safety update report (dsur)   pharmacovigilance and safety
Development safety update report (dsur) pharmacovigilance and safetyAzierta
 
US FDA Regulatory Submissions
US FDA Regulatory SubmissionsUS FDA Regulatory Submissions
US FDA Regulatory SubmissionsChandra Mohan
 
overview of Japan pharmaceutical regulatory authority - PMDA
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDANandhanan
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.Rovil Goel
 

Mais procurados (20)

IND INDA ANDA Application
IND INDA ANDA ApplicationIND INDA ANDA Application
IND INDA ANDA Application
 
FDA-Fast Track Designation
FDA-Fast Track DesignationFDA-Fast Track Designation
FDA-Fast Track Designation
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Regulatory guidelines of Australia
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australia
 
Orphan drugs
Orphan drugsOrphan drugs
Orphan drugs
 
Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan Drugs
 
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGSNEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
 
PHARMACOVIGILANCE TERMINOLOGIES ASKED IN INTERVIEWS
PHARMACOVIGILANCE TERMINOLOGIES ASKED IN INTERVIEWSPHARMACOVIGILANCE TERMINOLOGIES ASKED IN INTERVIEWS
PHARMACOVIGILANCE TERMINOLOGIES ASKED IN INTERVIEWS
 
Drug approval in US, EU & India
Drug approval in US, EU & IndiaDrug approval in US, EU & India
Drug approval in US, EU & India
 
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGSORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
 
Regulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaRegulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & India
 
ind
indind
ind
 
Post approval of drugs
Post approval of drugsPost approval of drugs
Post approval of drugs
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Development safety update report (dsur) pharmacovigilance and safety
Development safety update report (dsur)   pharmacovigilance and safetyDevelopment safety update report (dsur)   pharmacovigilance and safety
Development safety update report (dsur) pharmacovigilance and safety
 
US FDA Regulatory Submissions
US FDA Regulatory SubmissionsUS FDA Regulatory Submissions
US FDA Regulatory Submissions
 
overview of Japan pharmaceutical regulatory authority - PMDA
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDA
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.
 

Semelhante a The Orphan Drug Act

The science of hope
The science of hopeThe science of hope
The science of hopeFreedom Monk
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesKuldeep Badoniya
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan DrugsBill Smith
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug ReportBill Smith
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Harsha Rajasimha
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.docsuprajakotam
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Office of Health Economics
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigmsjalisman
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010HealthlinkWorldwide
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environmentspmaugeri
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...Dr Aneek Gupta
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...MedicineAndHealthUSA
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneAmerica's Health Insurance Plans
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2bahlinnm
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPMauro Placchi
 

Semelhante a The Orphan Drug Act (20)

The science of hope
The science of hopeThe science of hope
The science of hope
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research Incentives
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan Drugs
 
MMHA 6135 WK 5 App
MMHA 6135 WK 5 AppMMHA 6135 WK 5 App
MMHA 6135 WK 5 App
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.doc
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharma
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigms
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010
 
Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?
 
Twillman preventing rx abuse
Twillman preventing rx abuseTwillman preventing rx abuse
Twillman preventing rx abuse
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environments
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMP
 

The Orphan Drug Act

  • 1. The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.